Kidney and Urinary Tract Neoplasms with MCC: Inpatient Reimbursement Overview

DRG 686 addresses inpatient episodes for kidney and urinary tract neoplasms with a Major Complication or Comorbidity, encompassing complex surgical and medical management of advanced genitourinary cancers. Proper assignment affects Medicare inpatient reimbursement because this Diagnosis-Related Group reflects higher resource intensity and results in increased payment relative to lower-severity groupings.

Customize your policy alerts

Sign up for drg 686 policy alerts

Get alerted when payer policies referencing 686 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 686 Overview

DRG 686 covers hospital admissions for kidney and urinary tract neoplasms with a Major Complication or Comorbidity present, typically including complex oncologic resections, metastatic disease management, or severe treatment-related complications. This Diagnosis-Related Group groups cases with higher resource use due to intensive surgery, extended inpatient monitoring, or significant medical complications. It matters for Medicare payment because cases assigned here receive higher reimbursement to reflect increased length of stay, advanced perioperative care, and additional diagnostic or therapeutic interventions. Accurate coding of the Major Complication or Comorbidity influences reimbursement and case-mix reporting.

Clinical Trials

Perioperative and neoadjuvant therapy trials investigating systemic therapy given before or around nephrectomy for high-risk kidney and urinary tract neoplasms: these studies enroll patients with locally advanced renal cell carcinoma or urothelial tumors scheduled for partial or radical nephrectomy or nephroureterectomy to evaluate whether preoperative targeted or immunomodulatory regimens reduce tumor burden, increase margin-negative resections, or downstage nodal disease. This research is relevant because patients in DRG 686 often have complex surgical courses and major comorbidities (MCC), and perioperative strategies that safely improve resectability or reduce recurrence can affect length of stay, readmissions, and downstream costs. Providers and payers need evidence about perioperative safety, perioperative complication rates, and impact on short-term resource use in a high-risk inpatient population.
Comparative effectiveness and surgical technique trials comparing approaches and perioperative management for complex kidney and urinary tract tumor resections: these trials evaluate open versus minimally invasive (laparoscopic/robotic) nephrectomy or nephroureterectomy, variations in lymphadenectomy extent, and enhanced recovery after surgery (ERAS) protocols in patients with significant comorbidities or advanced tumor stage. The studies focus on inpatient outcomes such as operative complications, transfusion and ICU needs, in-hospital mortality, length of stay, and early post-discharge events among medically complex patients typical of DRG 686. Findings inform clinicians and payers about which surgical strategies and perioperative pathways yield better short-term outcomes and resource utilization for patients with MCC, guiding reimbursement and care pathway decisions.
Post-discharge outcomes and survivorship research evaluating readmission risk, renal function trajectory, and healthcare utilization after hospitalization for kidney or urinary tract neoplasm with major complications: these observational and interventional studies follow patients after discharge to identify predictors of 30- and 90-day readmission, progression to chronic kidney disease or dialysis, and patterns of outpatient oncology follow-up and palliative care use. Because this DRG captures patients with significant inpatient morbidity, understanding post-discharge needs and interventions that reduce readmissions or prevent renal deterioration is essential for care coordination, value-based payment models, and planning transitional services that can lower total cost of care for payers and improve outcomes for providers.

Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

652-KIDNEY-TRANSPLANT

Kidney Transplant: Inpatient Reimbursement Overview

653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

654-MAJOR-BLADDER-PROCEDURES-WITH-CC

Major Bladder Procedures with CC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 41

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical Trials

Perioperative and neoadjuvant therapy trials investigating systemic therapy given before or around nephrectomy for high-risk kidney and urinary tract neoplasms: these studies enroll patients with locally advanced renal cell carcinoma or urothelial tumors scheduled for partial or radical nephrectomy or nephroureterectomy to evaluate whether preoperative targeted or immunomodulatory regimens reduce tumor burden, increase margin-negative resections, or downstage nodal disease. This research is relevant because patients in DRG 686 often have complex surgical courses and major comorbidities (MCC), and perioperative strategies that safely improve resectability or reduce recurrence can affect length of stay, readmissions, and downstream costs. Providers and payers need evidence about perioperative safety, perioperative complication rates, and impact on short-term resource use in a high-risk inpatient population.
Comparative effectiveness and surgical technique trials comparing approaches and perioperative management for complex kidney and urinary tract tumor resections: these trials evaluate open versus minimally invasive (laparoscopic/robotic) nephrectomy or nephroureterectomy, variations in lymphadenectomy extent, and enhanced recovery after surgery (ERAS) protocols in patients with significant comorbidities or advanced tumor stage. The studies focus on inpatient outcomes such as operative complications, transfusion and ICU needs, in-hospital mortality, length of stay, and early post-discharge events among medically complex patients typical of DRG 686. Findings inform clinicians and payers about which surgical strategies and perioperative pathways yield better short-term outcomes and resource utilization for patients with MCC, guiding reimbursement and care pathway decisions.
Post-discharge outcomes and survivorship research evaluating readmission risk, renal function trajectory, and healthcare utilization after hospitalization for kidney or urinary tract neoplasm with major complications: these observational and interventional studies follow patients after discharge to identify predictors of 30- and 90-day readmission, progression to chronic kidney disease or dialysis, and patterns of outpatient oncology follow-up and palliative care use. Because this DRG captures patients with significant inpatient morbidity, understanding post-discharge needs and interventions that reduce readmissions or prevent renal deterioration is essential for care coordination, value-based payment models, and planning transitional services that can lower total cost of care for payers and improve outcomes for providers.

Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

652-KIDNEY-TRANSPLANT

Kidney Transplant: Inpatient Reimbursement Overview

653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

654-MAJOR-BLADDER-PROCEDURES-WITH-CC

Major Bladder Procedures with CC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 41

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Kidney and Urinary Tract Neoplasms with MCC: Inpatient Reimbursement Overview

Sign up for drg 686 policy alerts

DRG 686 Overview

Kidney and Urinary Tract Neoplasms with MCC: Inpatient Reimbursement Overview

Sign up for drg 686 policy alerts

DRG 686 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References